Loading
The hedgehog pathway inhibitor vismodegib shrank tumours in 43 percent of patients with locally advanced and 30 percent with metastatic basal cell carcinoma, becoming the first drug approved for advanced basal cell carcinoma.
Phase 2 study of 104 patients with metastatic (33) or locally advanced (71) basal cell carcinoma unsuitable for surgery or radiotherapy treated with vismodegib 150 mg daily.
Objective response was 30 percent in metastatic and 43 percent in locally advanced disease (21 percent complete), with median duration of response of 7.6 months; muscle spasms, alopecia, dysgeusia and weight loss were almost universal and led many patients to stop.
Vismodegib (and sonidegib) is the first-line systemic treatment for locally advanced or metastatic basal cell carcinoma, often given intermittently to manage side effects.
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.